5 completed, 3 unknown, 2 recruiting, 1 active not recruiting. 6 Phase 1, 3 Phase 2, 3 Phase 3, 1 Not applicable.
Follow Locally Advanced or Metastatic NSCLC: new trials by email Literature Review of Locally Advanced or Metastatic NSCLC trials Research Report on Locally Advanced or Metastatic NSCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy ASKC202+ Limertinib, Pemetrexed + Cisplatin /Carboplatin - Locally Advanced or Metastatic NSCLC | Phase 3 | Recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 286 | 2025-08-04 | 2026-08-19 |
| A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) HS-10504 - Locally Advanced or Metastatic NSCLC | Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 230 | 2024-06-26 | 2026-08-31 |
| A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer AK104, Tislelizumab, carboplatin - Locally Advanced or Metastatic NSCLC | Phase 3 | Not yet recruiting | Akeso | 642 | 2023-11-14 | 2023-08-14 |
| A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer WJ13404 tablets - Locally Advanced or Metastatic NSCLC | Phase 1 / Phase 2 | Terminated | Suzhou Junjing BioSciences Co., Ltd. | 14 | 2022-10-11 | 2025-09-08 |
| Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole Rifampicin; ASK120067, ASK120067;itraconazole - Locally Advanced or Metastatic NSCLC | Phase 1 | Completed | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 48 | 2022-06-06 | 2022-11-30 |
| Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy Locally Advanced or Metastatic NSCLC | Completed | AstraZeneca | 300 | 2020-03-30 | 2024-07-12 | |
| Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects ASK120067, ASK120067 in fed condition - Locally Advanced or Metastatic NSCLC | Phase 1 | Completed | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 24 | 2019-12-09 | 2020-04-29 |
| ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC ASK120067, Placebo Gefitinib 250 mg, Gefitinib - Locally Advanced or Metastatic NSCLC | Phase 3 | Unknown | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 337 | 2019-07-23 | 2024-06-14 |
| Whole Genomic Landscape of Advanced EGFR-mutant NSCLC Tagrisso - Locally Advanced or Metastatic NSCLC | Not applicable | Active not recruiting | Seoul National University Hospital | 148 | 2019-05-23 | 2026-04-24 |
| PBF-1129 in Patients With NSCLC PBF-1129 - Locally Advanced or Metastatic NSCLC | Phase 1 | Unknown | Palobiofarma SL | 18 | 2018-10-01 | 2024-02-09 |
| Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation Osimertinib 80 MG [Tagrisso] - Locally Advanced or Metastatic NSCLC | Phase 2 | Completed | Seoul National University Hospital | 15 | 2018-01-04 | 2025-02-11 |
| Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer ASK120067 - Locally Advanced or Metastatic NSCLC | Phase 1 / Phase 2 | Unknown | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 507 | 2017-11-30 | 2020-09-16 |
| Asia PDL1 Study Among NSCLC Patients Locally Advanced or Metastatic NSCLC | Completed | AstraZeneca | 658 | 2015-10-15 | 2018-02-28 |
Carcinoma, Non-Small-Cell Lung (13)
Bronchial Neoplasms (13) · Carcinoma, Bronchogenic (13) · Lung Diseases (13) · Lung Neoplasms (13) · Neoplasms (13) · Neoplasms by Site (13) · Respiratory Tract Diseases (13) · Respiratory Tract Neoplasms (13) · Thoracic Neoplasms (13)
Carboplatin (2) · Pemetrexed (2) · osimertinib (2) · Cisplatin (1) · Gefitinib (1) · Paclitaxel (1) · Rifampin (1) · tislelizumab (1)
Jiangsu Aosaikang Pharmaceutical Co., Ltd. (5) · AstraZeneca (2) · Seoul National University Hospital (2) · Akeso (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Palobiofarma SL (1) · Suzhou Junjing BioSciences Co., Ltd. (1)
China (10) · South Korea (3) · Japan (1) · United States (1)
Tae Min Kim, MD, PhD (2) · Hiroyuki Suzuki, Dr. (1) · Jie Wang, M.D. (1) · Juan Li (1) · Li Zhang, Prof. (1) · Noriyuki Ebi, Dr. (1) · Ping Yu, Prof. (1) · Qingming Wang (1) · Sang-We Kim, Prof. (1) · Weimin Li, Doctor (1) · Zourong Ruan (1)
PMID 35659581, PMID 37811634, PMID 38986212, PMID 40550238, PMID 40717496, PMID 41335275